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Abstract
Background: Network meta-analysis (NMA), a generalization of conventional MA, allows for assessing the relative
effectiveness of multiple interventions. Reporting bias is a major threat to the validity of MA and NMA. Numerous
methods are available to assess the robustness of MA results to reporting bias. We aimed to extend such methods
to NMA.
Methods: We introduced 2 adjustment models for Bayesian NMA. First, we extended a meta-regression model that
allows the effect size to depend on its standard error. Second, we used a selection model that estimates the
propensity of trial results being published and in which trials with lower propensity are weighted up in the NMA
model. Both models rely on the assumption that biases are exchangeable across the network. We applied the
models to 2 networks of placebo-controlled trials of 12 antidepressants, with 74 trials in the US Food and Drug
Administration (FDA) database but only 51 with published results. NMA and adjustment models were used to
estimate the effects of the 12 drugs relative to placebo, the 66 effect sizes for all possible pair-wise comparisons
between drugs, probabilities of being the best drug and ranking of drugs. We compared the results from the 2
adjustment models applied to published data and NMAs of published data and NMAs of FDA data, considered as
representing the totality of the data.
Results: Both adjustment models showed reduced estimated effects for the 12 drugs relative to the placebo as
compared with NMA of published data. Pair-wise effect sizes between drugs, probabilities of being the best drug
and ranking of drugs were modified. Estimated drug effects relative to the placebo from both adjustment models
were corrected (i.e., similar to those from NMA of FDA data) for some drugs but not others, which resulted in
differences in pair-wise effect sizes between drugs and ranking.
Conclusions: In this case study, adjustment models showed that NMA of published data was not robust to
reporting bias and provided estimates closer to that of NMA of FDA data, although not optimal. The validity of
such methods depends on the number of trials in the network and the assumption that conventional MAs in the
network share a common mean bias mechanism.
Keywords: Network meta-analysis, Publication bias, Small-study effect
Background
Network meta-analyses (NMAs) are increasingly being
used to evaluate the best intervention among different
existing interventions for a specific condition. The es-
sence of the approach is that intervention A is compared
with a comparator C, then intervention B with C, and
adjusted indirect comparison allows for comparing A
and B, despite the lack of any head-to-head randomized
trial comparing A and B. An NMA, or multiple-
treatments meta-analysis (MA), allows for synthesizing
comparative evidence for multiple interventions by com-
bining direct and indirect comparisons [1-3]. The pur-
pose is to estimate effect sizes for all possible pair-wise
comparisons of interventions, although some compari-
sons have no available trial.
Reporting bias is a major threat to the validity of results
of conventional systematic reviews or MAs [4,5]. Account-
ing for reporting biases in NMA is challenging, because
unequal availability of findings across the network of
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evidence may jeopardize NMA validity [6,7]. We previ-
ously empirically assessed the impact of reporting bias on
the results of NMAs of antidepressant trials and showed
that it may bias estimates of treatment efficacy [8].
Numerous methods have been used as sensitivity ana-
lyses to assess the robustness of conventional MAs to
publication bias and related small-study effects [9-20].
Modeling methods include regression-based approaches
and selection models. We extend these approaches to
NMAs in the Bayesian framework.
Methods
First, we extended a meta-regression model of the effect
size on its standard error, recently described for MAs
[21,22]. In this approach, the regression slope reflects
the magnitude of the association of effect size and preci-
sion (ie, the “small-study effect”), and the intercept pro-
vides an adjusted pooled effect size (ie, the predicted
effect size of a trial with infinite precision). Second, we
introduced a selection model, which models the prob-
ability of a trial being selected and is taken into account
with inverse weighting in the NMA. Both adjustment
models rely on the assumption that biases are exchange-
able across the network, ie, biases, if present, operate in
a similar way in trials across the network. Third, we ap-
plied these adjustment models to datasets created from
US Food and Drug Administration (FDA) reviews of
antidepressant trials and from their matching publica-
tions. These datasets were shown to differ because of
reporting bias [23]. We compared the results of the
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Figure 1 Contour-enhanced funnel plots for the antidepressant trials with published results. Each funnel plot is the scatter plot of the
treatment effect estimates from individual trials against the associated standard errors; the vertical solid line represents the pooled estimate. In
the absence of reporting bias, we might expect a symmetrical funnel plot. We may find the funnel plot is not symmetrical, ie does not resemble
an inverted funnel, which may be due to reporting bias, however there are other possible sources of asymmetry. The contour lines represent
perceived milestones of statistical significance (long dash p = 0.1; dash p= 0.05; short dash p= 0.01). If studies seem to be missing in areas of non-
significance then asymmetry may be due to reporting bias rather than other factors.
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adjustment models applied to published data and stand-
ard NMA for published and for FDA data, the latter
considered the reference standard.
Datasets used
A previous review by Turner et al. assessed the selective
publication of antidepressant trials [23]. The authors
identified all randomized placebo-controlled trials of 12
antidepressant drugs approved by the FDA and then
publications matching these trials by searching literature
databases and contacting trial sponsors. From the FDA
database, the authors identified 74 trials, among which
results for 23 trials were unpublished. The proportion of
trials with unpublished results varied across drugs, from
0% for fluoxetine and paroxetine CR to 60% and 67% for
sertraline and bupropion (Additional file 1: Appendix 1).
These entire trials remained unpublished depending on
the nature of the results. Moreover, in some journal arti-
cles, specific analyses were reported selectively and effect
sizes differed from that in FDA reviews. The outcome
was the change from baseline to follow-up in depression
severity score. The measure of effect was a standardized
mean difference (SMD). Separate MAs of FDA data
showed decreased efficacy for all drugs as compared to
published data, the decrease in effect size ranging from
10% and 11% for fluoxetine and paroxetine CR to 39%
and 41% for mirtazapine and nefazodone (Additional file 1:
Appendix 1). Figure 1 shows the funnel plots of pub-
lished data. Visual inspection does not suggest stronger
treatment benefit in small trials (ie, funnel plot asym-
metry) for any of the 12 comparisons of each drug and
placebo.
Network meta-analysis
The standard model for NMA was formalized by Lu and
Ades [2,24,25]. We assume that each trial i assessed
treatments j and k among the T interventions in the net-
work. Each trial provided an estimated intervention ef-
fect size yijk of j over k and its variance vijk. We assume
that yijk > 0 indicates superiority of j over k. Assuming
normal likelihood and according to a random-effects
model, yijkN(θijk,vijk) and θijkeN Θjk ; τ2 , where θijk is
the true effect underlying each randomized comparison
between treatments j and k and Θjk is the mean of the
random-effects effect sizes over randomized compari-
sons between treatments j and k. The model assumes
homogeneous variance (ie, τjk
2 = τ2). This assumption can
be relaxed [2,26]. The model also assumes consistency
between direct and indirect evidence: if we consider
treatment b as the overall network baseline treatment,
the treatment effects of j, k, etc. relative to treatment b,
Θjb , Θkb , etc., are considered basic parameters, and the
remaining contrasts, the functional parameters, are
derived from the consistency equations Θjk ¼ Θjb  Θkb
for every j, k 6¼ b.
Adjustment models
Meta-regression model
We used a network meta-regression model extending a
regression-based approach for adjusting for small-study
effects in conventional MAs [21,22,27-29]. This regression-
based approach takes into account a possible small-study
effect by allowing the effect size to depend on a measure of
its precision. Here, we assume a linear relationship be-
tween the effect size and its standard error and the model
involves extrapolation beyond the observed data to a hypo-
thetical study of infinite precision. The extended model for
NMA is as follows:
yijkeN γ ijk ; vijk
 
γijk ¼ θijk þ Iijk  βjk 
ﬃﬃﬃﬃﬃﬃ
vijk
p
βjkeN β; σ2 
θijkeN Θjk ; τ2 
Θjk ¼ Θjb  Θkb for every j, k 6¼ b
Figure A in Additional file 2 shows a graphical repre-
sentation of the model. In the regression equation, θijk is
the treatment effect adjusted for small-study effects
underlying each randomized comparison between treat-
ments j and k; βjk represents the potential small-study
effect (ie, the slope associated with funnel plot asym-
metry for the randomized comparisons between treat-
ments j and k). The model assumes that these
comparison-specific regression slopes follow a common
normal distribution, with mean slope β and common
between-slopes variance σ2. This is equivalent to the as-
sumption that comparison-specific small-study biases
are exchangeable within the network. Since we assumed
that yijk > 0 indicates superiority of j over k, β > 0 would
mean an overall tendency for a small-study effect (ie,
treatment contrasts tend to be over-estimated in smaller
trials). Finally, Iijk is equal to 1 if a small-study effect is
expected to favor treatment j over k, equal to −1 if a
small-study effect is expected to favor treatment k over j,
and equal to 0 when one has no reason to believe that
there is bias in either direction (e.g., for equally novel ac-
tive vs. active treatment). In trials comparing active and
inactive treatments (e.g., placebo, no intervention), we
can reasonably expect the active treatment to be always
favored by small-study bias.
Selection model
We use a model that adjusts for publication bias using a
weight function to represent the process of selection.
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The model includes an effect size model (ie, the stand-
ard NMA model that specifies what the distributions of
the effect size estimates would be with no selection) and
a selection model that specifies how these effect size dis-
tributions are modified by the process of selection
[14,30]. We assume that the probability of selection
depends on the standard error of the effect size, as a
decreasing function of it. We adopt an approach based
on a logistic selection model, as previously used in con-
ventional MAs [18,31].
yijkeN γ ijk ; vijk
 
γijk ¼ θijk=wi
logitwi ¼ β0jk þ β1jk  Iijk 
ﬃﬃﬃﬃﬃﬃ
vijk
p
β0jkN(β0, σ02) and β1jkN(β1, σ12)
θijkeN Θjk ; τ2 
Θjk ¼ Θjb  Θkb for every j, k 6¼ b
Figure B in Additional file 2 shows a graphical repre-
sentation of the model. In the logistic regression equa-
tion, wi represents the propensity of the trial results to
be published, β0jk sets the overall probability of observ-
ing a randomized comparison between treatments j and
k, and β1jk controls how fast this probability evolves as
the standard error increases. We expect β1jk to be nega-
tive, so trial results yielding larger standard errors have
lower propensity to be published. The model assumes
exchangeability of the β0jk and β1jk coefficients within
the network. By setting γijk= θijk/wi, we define a simple
scheme that weights up trial results with lower propen-
sity of being published so that they have a dispropor-
tionate influence in the NMA model. θijk is the
treatment contrast corrected for the selection process
underlying each randomized comparison between treat-
ments j and k. Finally, Iijk is defined in the same way as
in the preceding section.
Models estimation
We estimated 4 models: standard NMA model of pub-
lished data, 2 adjustment models of published data and a
standard NMA model of FDA data. In each case, model
estimation involved Markov chain Monte Carlo methods
with Gibbs sampling. Placebo was chosen as the overall
baseline treatment to compare all other treatments.
Consequently, the 12 effects of drugs relative to placebo
are the basic parameters. For 2 treatments j and k,
SMDjk > 0 indicate that j is superior to k. In both the
meta-regression and selection models, we assumed that
the active treatments would always be favored by small-
study bias as compared to placebo; consequently, Iijk is
always equal to 1.
In the standard NMA model, we defined prior distri-
butions for the basic parameters Θjb and the common
variance τ2: ΘjbeN 0; 1002ð Þ and τeUniform 0; 10ð Þ . In
the meta-regression model, we further chose vague
priors for the mean slope β and common between-
slopes variance σ2: βeN 0; 1002ð Þ and σeUniform 0; 10ð Þ .
In the selection model, we chose weakly informative
priors for the central location and dispersion parameters
(β0, σ0
2) and (β1, σ1
2). We considered pmin and pmax the
probability of publication when the standard error takes
its minimum and maximum values across the network
of published data and specified beta priors for these
probabilities [32]. The latter was achieved indirectly by
specifying prior guesses for the median and 5th or 95th
percentile [33]. For trials with standard error equal to
the minimum observed value, we assumed that the
chances of pmin being < 50% were 5% and the chances of
pmin being < 80% were 50%. For trials with standard error
equal to the maximum observed value, our guess was
that the chances of pmax being < 40% were 50% and the
chances of pmax being < 70% were 95%. We discuss these
choices further in the Discussion. From this information,
we determined Beta(7.52, 2.63) and Beta(3.56, 4.84) as
prior distributions for pmin and pmax, respectively. Fi-
nally, we expressed β0 and β1 in terms of pmin and pmax
and chose uniform distributions in the range (0,2) on
the standard deviations σ0 and σ1. For each analysis, we
constructed posterior distributions from 2 chains of
500,000 simulations, after convergence achieved from an
initial 500,000 simulations for each (burn-in). Analysis
involved use of WinBUGS v1.4.3 (Imperial College and
MRC, London, UK) to estimate all Bayesian models and
R v2.12.2 (R Development Core Team, Vienna, Austria)
to summarize inferences and convergence. Codes are
reported in the Additional file 1: Appendix 2.
Models comparison
We compared the results of the 2 adjustment models ap-
plied to published data and results of the standard NMA
model applied to published data and the FDA data, the
latter considered the reference standard. First, we com-
pared posterior means and 95% credibility intervals for
the 12 basic parameters and common variance, as well as
for the 66 functional parameters (ie, all 12× 11/2= 66 pos-
sible pair-wise comparisons of the 12 drugs). Second, we
compared the rankings of the competing treatments. We
assessed the probability that each treatment was best, then
second best and third best, etc. We plotted the cumulative
probabilities and computed the surface under the cumula-
tive ranking (SUCRA) line for each treatment [34]. Third,
to compare the different models applied to published data,
we used the posterior mean of the residual deviance and
the deviance information criteria [35].
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Results
In the meta-regression model applied to published data,
the posterior mean slope β was 1.7 (95% credible interval
−0.3–3.6), which suggests an overall tendency for a small-
study effect in the network. The 12 regression slopes were
similar, with posterior means ranging from 1.4 to 1.9. In
the selection model applied to published data, the mean
slope β1 was −10.0 (−18.0 – -2.50), so trials yielding larger
standard errors tended overall to have lower propensity to
be published. In both models, all estimates were subject to
large uncertainty (Additional file 1: Appendix 3).
Table 1 shows the estimates of the 12 basic parameters
between each drug and placebo according to the 4 mod-
els. As compared with the NMA of published data, both
adjustment models of published data showed that the
whole 12 estimated drug effects relative to placebo were
reduced. For the meta-regression model, the decrease in
efficacy ranged from 48% for venlafaxine XR to 99% for
fluoxetine. For the selection model, the decrease ranged
from 13% for escitalopram to 26% for paroxetine. When
considering the functional parameters (ie, the 66 pos-
sible pair-wise comparisons between drugs), we found
differences between the results of adjustment models
and the standard NMA model applied to published trials
(Figure 2). The median relative difference, in absolute value,
between pair-wise effect sizes from the regression model
and the standard NMA model was 57.3% (25% – 75% per-
centile 30.3% – 97.6%); the median relative difference be-
tween the selection model and the standard NMA model
was 29.2% (15.1% – 46.1%).
Figure 3 summarizes the probabilities of being the best
antidepressant. Compared to the standard NMA of pub-
lished data, adjustment models of published data yielded
decreased probabilities of the drug being the best for
paroxetine (from 41.5% to 20.7% with the regression
model or 25.7% with the selection model) and mirtaza-
pine (from 30.3% to 15.7% or 21.9%). They yielded
increased probabilities of the drug being the best for
venlafaxine (from 7.9% to 10.6% or 12.8%) and venlafax-
ine XR (from 14.1% to 21.0% or 23.5%).
Figure 4 shows cumulative probability plots and
SUCRAs. For the standard NMA of published data,
paroxetine and mirtazapine tied for first place and venla-
faxine XR and venlafaxine tied for third. The selection
model applied to published data yielded a slightly differ-
ent ranking, with paroxetine, mirtazapine and venlafax-
ine XR tying for first and venlafaxine was fourth. In the
regression model applied to published data, venlafaxine
XR was first, venlafaxine and paroxetine tied for second
and mirtazapine was fifth.
In adjustment models applied to published data,
between-trial heterogeneity and fit were comparable to
those obtained with standard NMA of published data
(Tables 1 and 2).
The estimated drug effects relative to placebo from the
regression and selection models were similar to those
from the NMA of FDA data for some drugs (Table 1).
There were differences when considering the 66 possible
pair-wise comparisons between drugs (Figure 5). Results
also differed by models regarding the probability of
Table 1 Comparison of network meta-analysis (NMA)-based estimates between the 2 adjustment models applied to
published data and the standard NMA model applied to US Food and Drug Administration (FDA) data and to
published data
FDA data Published data
Standard NMA model Regression model Selection model Standard NMA model
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
ΘBUP 0.176 (0.081) 0.043 (0.256) 0.229 (0.121) 0.271 (0.139)
ΘCIT 0.240 (0.074) 0.081 (0.171) 0.254 (0.073) 0.306 (0.076)
ΘDUL 0.300 (0.054) 0.166 (0.190) 0.340 (0.066) 0.402 (0.058)
ΘESC 0.310 (0.067) 0.165 (0.193) 0.311 (0.070) 0.357 (0.068)
ΘFLU 0.256 (0.081) 0.004 (0.160) 0.215 (0.068) 0.271 (0.074)
ΘMIR 0.351 (0.070) 0.206 (0.331) 0.424 (0.110) 0.567 (0.092)
ΘNEF 0.256 (0.076) 0.112 (0.260) 0.348 (0.094) 0.437 (0.094)
ΘPAR 0.426 (0.063) 0.267 (0.346) 0.438 (0.105) 0.593 (0.078)
ΘPAR CR 0.323 (0.101) 0.174 (0.187) 0.309 (0.083) 0.354 (0.085)
ΘSER 0.252 (0.077) 0.210 (0.231) 0.359 (0.094) 0.419 (0.094)
ΘVEN 0.395 (0.071) 0.199 (0.224) 0.403 (0.092) 0.504 (0.075)
ΘVEN XR 0.398 (0.094) 0.261 (0.273) 0.423 (0.110) 0.506 (0.107)
τ 0.060 (0.037) 0.031 (0.024) 0.024 (0.019) 0.032 (0.025)
Data are posterior means and standard deviations of the basic parameters (Θ), the between-trial heterogeneity (τ).
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being the best drug and the ranking of drugs. In the
standard NMA of FDA data, the probability of being the
best drug was 7.3% for mirtazapine, 33.9% for paroxe-
tine, 19.3% for venlafaxine, and 25.7% for venlafaxine
XR (Figure 3); paroxetine ranked first, and venlafaxine
and venlafaxine XR tied for second (Figure 4).
Discussion
We extended two adjustment methods for reporting bias
from MAs to NMAs. The first method combined NMA
and meta-regression models, with effect sizes regressed
against their precision. The second one combined the
NMA model with a logistic selection model estimating
the probability that a trial was published or selected in
the network. The former method basically adjusts for
funnel plot asymmetry or small study effects, which may
arise from causes other than publication bias. The latter
adjusts for publication bias (ie, the suppression of an en-
tire trial depending on results). The two models borrow
strength from other trials in the network with the as-
sumption that biases operate in a similar way in trials
across the domain.
In a specific network of placebo-controlled trials of
antidepressants, based on data already described and
published previously by Turner et al., comparing the
results of adjustment models applied to published data
and those of the standard NMA model applied to pub-
lished data allowed for assessing the robustness of effi-
cacy estimates and ranking to publication bias or related
small-study effects. Both models showed a decrease in
all basic parameters (ie, the 12 effect sizes of drugs rela-
tive to placebo). The 66 contrasts for all possible pair-
wise comparisons between drugs, the probabilities of
being the best drug and the ranking were modified as
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Figure 2 Difference plots of estimates of pair-wise comparisons of the 12 antidepressant agents and placebo: regression model of
published data vs. standard network meta-analysis (NMA) model of published data (left panel); selection models of published vs.
standard NMA model of published data (right panel). The x-axes show the estimates from the standard NMA model applied to published
data, the y-axes show the differences between the estimates from the adjustment (regression or selection) model of published data and the
estimates from the standard NMA model of published data. Black dots are the 12 estimated drug effects relative to placebo; white dots are the
66 possible pair-wise comparisons between the 12 drugs.
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well. The NMA of published data was not robust to
publication bias and related small-study effects.
This specific dataset offered the opportunity to per-
form NMAs on both published and FDA data. The latter
may be considered "an unbiased (but not the complete)
body of evidence" for placebo-controlled trials of antide-
pressants [28]. The comparison of the results of the 2
models applied to published data and the standard
NMA model applied to FDA data showed that the effect
sizes of drugs relative to placebo were corrected for
some but not all drugs. This observation led to differ-
ences in the 66 possible pair-wise comparisons between
drugs, the probabilities of being the best drug and the
ranking. It suggests that the 2 models should not be
considered optimal; that is, the objective is not to pro-
duce definitive estimates adjusted for publication bias
and related small-study effects but rather to assess the
robustness of results to the assumption of bias.
Similar approaches have been used by other authors.
Network meta-regression models fitted within a Bayesian
framework were previously developed to assess the impact
of novelty bias and risk of bias within trials [36,37].
Network meta-regression to assess the impact of small-
study effect was specifically used by Dias et al. in a re-
analysis of a network of published head-to-head rando-
mized trials of selective serotonin reuptake inhibitors
[38]. Along the line of the regression-based approach of
Moreno et al. in conventional MA, the authors intro-
duced a measure of study size as a regression variable
within the NMA model and identified a mean bias in
pair-wise effect sizes. More recently, Moreno et al. used
a similar approach to adjust for small-study effects in
several conventional MAs of similar interventions and
outcomes and illustrated their method using the dataset
of Turner et al. [39]. Our approach differed in that we
extended this meta-regression approach to NMAs. We
used the standard error of treatment effect estimate as
the regressor. As well, we specified an additive between-
trial variance rather than a multiplicative overdispersion
parameter. With the latter, the estimated multiplicative
parameter may be < 1, which implies less heterogeneity
than would be expected by chance alone. Selection model
FDA data Regression Selection Published
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approaches have been considered recently. Chootrakool
et al. introduced an approximated normal model based on
empirical log-odds ratio for NMAs within a frequentist
framework and applied Copas selection models for some
groups of trials in the network selected according to
funnel plot asymmetry [40]. Mavridis et al. presented a
Bayesian implementation of the Copas selection model
extended to NMA and applied their method on the
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Figure 4 Cumulative ranking probability plots for the 12 antidepressant agents from the standard NMA model applied to FDA data
(bold solid line) and published data (bold dotted line) and from the 2 adjustment models applied to published data (regression model
in plain dashed line and selection model in plain double-dashed line). On each plot, the x-axis shows possible ranks from r= 1 up to r= 13
and the y-axis shows the cumulative probabilities that the corresponding treatment is among the top r treatments. The closer the curve is to the
upper left corner, the better the treatment. The surface under the cumulative ranking line is 1 when a treatment is the best and 0 when a
treatment is the worst. FDA: standard NMA model applied to FDA data (bold plain line); Pub.: standard NMA model applied to published data
(bold dash line); Reg.: regression model applied to published data (dash line); Sln.: selection model applied to published data (long-dash short-
dash line).
Table 2 Comparison of fit and complexity between the 2 adjustment models and the standard NMA model, all applied
to published data
Regression model Selection model NMA model
Mean posterior residual deviance (Dres) 31.4 31.5 34.4
Effective number of parameters (pD) 15.9 14.7 13.9
Deviance Information Criterion (DIC) 47.3 46.2 48.3
Lower values of Dres indicate a better fit to the data. Lower values of the DIC indicate a better compromise between model fit and model complexity. A difference
in DICs of 5 or more can be considered substantial (http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/dicpage.shtml).
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network of Turner et al. [41]. In the Copas selection
model, the selection probability depends on both the esti-
mates of the treatment effects and their standard errors.
In the extension to NMA, an extra correlation parameter
ρ, assumed equal for all comparisons, needs to be esti-
mated. When applied to published data of the network of
Turner et al., the selection model we proposed and the
treatment-specific selection model of Mavridis et al.
yielded close results.
The 2 adjustment models rely on the assumption of
exchangeability of selection processes across the network;
that is, biases, if present, operate in a similar way in trials
across the network. In this case study, all studies were, by
construction, industry-sponsored, placebo-controlled trials
registered with the FDA, and for all drugs, results of entire
studies remained unreported depending on the results
[23]. Thus, the assumption of exchangeability of selection
processes is plausible. More generally, if we have no infor-
mation to distinguish different reporting bias mechanisms
across the network, an exchangeable prior distribution is
plausible, "ignorance implies exchangeability" [42,43].
However, the assumption may not be tenable in other
contexts in which reporting biases may affect the network
in an unbalanced way. It may operate differently in
placebo-controlled and head-to-head trials [44], in older
and more recent trials (because of trial registries), and for
drug and non-drug interventions [7]. In more complex
networks involving head-to-head trials, the 2 adjustment
models could be generalized to allow the expected publi-
cation bias or small-study bias for active-active trials to
differ from that of the expected bias in trials comparing
active and inactive treatments [36]. In head-to-head trials,
the direction of bias is uncertain but assumptions in defin-
ing Iijk could be that the sponsored treatment is favored
(sponsorship bias) [45,46] or that the newest treatment is
favored (optimism bias) [37,47,48]. If treatment j is the
drug provided by the pharmaceutical that sponsored the
trial and treatment k is not, Iijk would be equal to 1. Or
Iijk would be equal to 1 if treatment j is newer than treat-
ment k. However, disentangling the sources of bias
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Figure 5 Difference plots of estimates of pair-wise comparisons of the 12 antidepressant agents and placebo: standard NMA model of
published data vs. standard NMA model of FDA data (upper panel); regression model of published data vs. standard NMA model of
FDA data (bottom left panel); selection model of published vs. standard NMA model of FDA data (bottom right panel). The x-axes show
the estimates from the standard NMA model applied to FDA data, the y-axes show the differences between the estimates from the adjustment
(regression or selection) model of published data and the estimates from the standard NMA model of FDA data. Black dots are the 12 estimated
drug effects relative to placebo; white dots are the 66 possible pair-wise comparisons between the 12 drugs.
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operating on direct and indirect evidence would be diffi-
cult, especially if reporting bias and inconsistency are
twisted together or if the assumed bias directions are in
conflict on a loop.
The models we described have limitations. First, they
would result in poor estimation of bias and effect sizes
when the conventional MAs within the network include
small numbers of trials [21]. Second, for the selection
model, we specified the weight function. If the underlying
assumptions (ie, a logistic link form and the chance of a
trial being selected related to standard error) are wrong,
the estimated selection model will be wrong. However, al-
ternative weight functions (e.g., probit link) or conditioning
(e.g., on the magnitude of effect size) could be considered.
Finally, it was implemented with a weakly informative prior,
which mainly suggested that the propensity for results to be
published may decrease with increasing standard error.
There is a risk that prior information overwhelms observed
data, especially if the number of trials is low. Although they
were somewhat arbitrarily set, our priors for the selection
model parameters were in line with the values in previous
studies using the Copas selection model [12,49]. Different
patterns of selection bias could be tested, for instance, by
considering various prior modes for pmin and pmax, the
probabilities of publication when the standard error takes its
minimum and maximum values across the network [15].
Conclusions
In conclusion, addressing publication bias and related
small-study effects in NMAs was feasible in this case
study. Validity may be conditioned by sufficient numbers
of trials in the network and assuming that conventional
MAs constituting the network share a common mean
bias. Simulation analyses are required to determine
under which condition such adjustment models are
valid. Application of such adjustment models should be
replicated on more complex networks, ideally represent-
ing the totality of the data as in Turner's, but our results
confirm that authors and readers should interpret
NMAs with caution when reporting bias has not been
addressed.
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